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Abstract
Gout is a frequent inflammatory disease induced by the deposition of monosodium urate crystals in joints and extra-
articular tissues. The natural history of the disease includes four different phases: asymptomatic hyperuricemia, acute attacks, 
intercritical phase, and chronic tophaceous gout. Imaging techniques have several applications in the diagnosis, clinical moni-
toring and management of the disease but, particularly, musculoskeletal ultrasound is able to detect a wide set of abnormalities 
in gout. This review reports the most relevant findings detectable by ultrasound and the current available data in the literature 
regarding the role of musculoskeletal ultrasound in gout.
Keywords: gout, monosodium urate crystals, ultrasound
Musculoskeletal ultrasonography in gout
Chiara Scirocco, Iolanda Maria Rutigliano, Annacarla Finucci, Annamaria Iagnocco
Rheumatology Unit, Dipartimento Medicina Interna e Specialità Mediche, Sapienza Università di Roma, Rome, Italy
Received 30.09.2015 Accepted 21.10.2015  
Med Ultrason  
2015, Vol. 17, No 4, 535-540 
Corresponding author: Annamaria Iagnocco, 
 Ultrasound Unit, Reumatology,  
 Sapienza Università di Roma,  
 V.le del Policlinico 155, Rome – 00161, Italy.  
 Phone: +39 06 49974634, Fax: +39 06 49974642 
 E-mail: annamaria.iagnocco@uniroma1.it
Introduction
Gout is an inflammatory disease induced by the depo-
sition of monosodium urate (MSU) crystals in joint and 
extra-articular tissues [1]. It is the most common form of 
arthritis in men older than 40 years [2] and its prevalence 
has increased in the general population in the last decade 
[3].
Hyperuricaemia, defined as a serum urate level of 
≥6.8 mg/dl (6.8 mg/dl represent the limit of urate solubil-
ity at physiologic temperature and pH), is a necessary, 
but not sufficient, condition for the development of the 
disease [4]. It is due to an overproduction of urate or, 
more frequently, to reduced renal excretion; the majority 
(over 80%) of gouty patients have a positive family his-
tory of gout or hyperuricemia [5]. 
The natural history of gout includes four different 
phases: asymptomatic hyperuricemia, acute attacks, in-
tercritical phase, and chronic tophaceous gout [6]. Ini-
tially, acute attacks (that typically resolve without thera-
py in 7 to 10 days) alternate with asymptomatic periods. 
Afterwards, if untreated, gout evolves in a chronic form 
with polyarticular attacks, symptoms present also be-
tween attacks and deposition of crystals (tophi) in soft 
tissues or joints, with the development of necrosis and fi-
brous proliferation and progressive joint destruction [1]. 
There is evidence that acute arthritis attacks are triggered 
by the deposition of MSU crystals in joints and soft tis-
sues in which they act as “danger signals”. This event 
leads to an inflammatory pathway with the activation of 
the inflammasome complex [nucleotide binding domain 
and leucin-rich repeat containing protein (NLRP)] with 
consequent release of interleukin (IL)-1β and other in-
flammatory mediators [1,7]. Synovial lining cells and 
phagocytes are responsible for further persistence of 
inflammation and tissue damage [1]. In a recent study, 
Pineda et al [8] reproduced the gout attack in 42 rabbits 
injecting crystals in their knee joints; then they compared 
clinical, histological, and ultrasonographic findings with 
the control group. The authors evaluated and described 
the early morphostructural changes observed by ultra-
sonography (US) during an acute gout attack.
Typical clinical and laboratory findings can induce 
the suspicion of gout, but the demonstration of MSU 
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crystals in aspirated joint fluid or tophi is necessary for a 
definitive diagnosis [9]. However, this is not always pos-
sible or easy to perform.
Different studies have enhanced that gout manage-
ment remains suboptimal and that there are few validated 
markers of disease activity [10-12]. This is an urgent 
problem to face. Indeed, chronic articular inflammation 
can lead to joint impairment and disability. Furthermore, 
uncontrolled hyperuricemia is associated with renal and 
cardiovascular disease [13-17] with overall increased 
morbidity and mortality [16,18].
Imaging modalities, such as conventional radiogra-
phy (CR), musculoskeletal ultrasonography (US), com-
puterized tomography (CT), and magnetic resonance 
(MRI) have several applications in the diagnosis, clinical 
monitoring and management of gout pathology, even if 
they are not included in the gout classification criteria 
[19]. Recently, the OMERACT Gout group reported the 
value of the different imaging modalities as measure-
ment instruments for outcomes in studies of people with 
chronic gout, and evidenced which should be domains 
for imaging in gout and identified a research agenda 
about this issue [20].
Musculoskeletal US is an imaging tool characterized 
by a wide set of advantages. It is a not invasive, safe, 
easily accessible and a well-accepted imaging technique 
by the patient, relatively cheap and without any specific 
contra-indication [21]. Crystalline materials, present 
in joints or soft tissues, reflect ultrasound waves more 
strongly compared with surrounding tissues and are thus 
are easily distinguishable. Differently from the others 
imaging modalities, US can be useful for the diagnosis 
and management of gout from the initial manifestations 
of the disease.
Nowadays, the role of US in the detection of synovial 
and cortical bone lesions in rheumatoid arthritis (RA) 
is well established [22-25]. Different studies have dem-
onstrated its capability to show both inflammatory and 
structural damage lesions in patients affected by osteo-
arthritis (OA) [26-29]. Moreover, its role is now more 
defined in the assessment of joint and soft tissue involve-
ment in patients affected by connective tissue diseases 
(CTD) [30]. At the same extent, the usefulness of US in 
gout is progressively increasing. The aim of this review 
is to report the current available data present in the lit-
erature regarding the role of musculoskeletal US in the 
assessment of patients affected by gout.
US findings in gout
According to the literature, the US findings in gout 
can be differentiated in specific and non-specific signs of 
the disease [31,32]. Typical structures for MSU deposits 
are: hyaline cartilage, synovial fluid, bone, tendons, and 
soft tissues.
Non specific findings
Inflammatory abnormalities (joint effusion and syno-
vial hypertrophy) and structural lesions (bone erosions) 
can be detected in gout patients; however, they are not 
specific for this condition [31,32]. Joint effusion is de-
fined as an abnormal hypoechoic or anechoic intraar-
ticular material that is displaceable and compressible but 
does not exhibit a Doppler signal; synovial hypertrophy 
appears as an abnormal hypoechoic intraarticular tissue 
that is not displaceable and is poorly compressible and 
may or not exhibit hypervascularisation with Doppler 
techniques [33]. Joint effusion is a frequent finding in 
gout and the presence of hyperechoic spots within ef-
fusion may be suggestive for the disease, being related 
to the presence of crystals aggregates. These aggregates 
have less than 1 mm and, during the examination, when 
pressing the probe on the surface of the examined struc-
ture, they float inside the joint realizing a characteristic 
“snowstorm appearance” [34,35]. Using US it is possible 
to identify joints with effusion and to perform US-guided 
aspiration with the aim of identifying crystals at syno-
val fluid analysis, which is considered the gold standard 
for the diagnosis [9]. Synovial hypertrophy and hyper-
vascularisation can be also detected and, even though 
they are non specific findings, the possible presence of 
hyperechoic spots or cloudy areas in the synovium are 
strongly evocative for gout [34]. The presence of power 
Doppler signal indicates, as well as in the other forms of 
arthritis, active inflammation. It is sometimes possible to 
detect it even in clinically non inflamed joints, having the 
possibility to highlight a subclinical state of inflamma-
tion. Moreover, it has been demonstrated that the signal 
may disappear after treatment [32,36]. Bone erosions are 
defined as intra-articular discontinuity of the bone sur-
face in two perpendicular planes [33]. They are present 
in the late stage of the disease and their presence corre-
lates directly with the number of acute attacks, duration 
of disease, and presence of tophi. Characteristic sites for 
erosions are represented by the medial aspect of the first 
metatarsophalangeal joint, that is the most frequent, and 
the metacarpophalangeal joints [37,38]. Gout erosions 
cannot be differentiated from other erosive inflammatory 
arthropathies and no specific scoring systems, different 
from those used in RA, have been reported [32,39].
Specific signs of gout
The three different features that are considered as 
characteristic signs of gout are: double contour sign, ag-
gregates and tophi. Recently, OMERACT definitions for 
gouty lesions have been published [40].
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Double contour sign (DCS) is defined as an abnor-
mal hyperechoic band over the superficial margin of the 
articular hyaline cartilage, independent of the angle of 
insonation, irregular or regular, continuous or intermit-
tent, that can be distinguished from the cartilage inter-
face sign [40]. This is due to the fact that MSU crystal-
lize on the superficial margin of the cartilage so crystals 
deposits are mainly located on the superficial margin 
of the hyaline cartilage; contrarily, hyperechoic spots 
within the cartilage layer are suggestive for calcium 
pyrophosphate deposits [41]. DCS is considered one of 
the most specific features of this pathology; according 
to the evidence this finding has a sensitivity of 46.3 % 
and a specificity of 99% [42-45]. It is more frequently 
detected in symptomatic joints, particularly at the level 
of the metatarsophalangeal (especially the first) and 
metacarpophalangeal joints and at the hyaline cartilage 
of the knees. The visualization of DCS may be difficult 
in joints with limited width of the acoustic window for 
cartilage assessment as well as in osteoarthritic joint 
and in presence of effusion, which induces a posterior 
echo enhancement [31,35]. Interestingly, DCS has been 
found even in patients with asymptomatic hyperuricae-
mia [46,47] and it has been reported that it may disap-
pear after therapy [48].
Aggregates, due to the deposition of MSU crystals in 
synovial fluids and other tissues, such as cartilage and 
soft tissues, are considered the landmark of gout. These 
aggregates reflect ultrasound beams more intensely than 
the surrounding tissues and their reflectivity is less influ-
enced by the angle of insonation [31,32,35,49]. Accord-
ing to their different features (dimension, localization, 
and local reaction) and to the stage of the disease, three 
types of aggregates can be identified: hyperechoic spots, 
hyperechoic cloudy areas, and tophi [32,49]. Hyperecho-
ic spots are bright dotted foci smaller than 1 mm, pre-
sent within joint effusion (non specific), in hypertrophic 
synovium, or tophi (specific). Hyperechoic cloudy areas 
(“cottony images”) [37] are aggregates smaller than 1 
cm, usually homogeneous and without posterior acoustic 
shadow; they are considered as typical lesions of gout 
and are highly responsive to therapy [32,50]. Tophi, ex-
tracellular deposits of MSU surrounded by foreign body 
giant cells and mononuclear cells, forming a granuloma-
like structure, can be found in any site and can be clas-
sified as soft, hard, and mixed [35,51,52]. Initially, tophi 
are soft on palpation, nodular, small, with homogeneous 
structure (soft tophi). After time, they become non-ho-
mogenous, bigger, and harder on palpation, frequently 
with calcifications inside and posterior acoustic shadow 
(hard and mixed tophi). The prevalence of tophi increas-
es with the disease evolution [38].
Discussions
Different studies have recently addressed the role 
of US in gout. They evaluated not only the different le-
sions to be searched, but also the sites to be investigated 
[53,54] in order to improve the sensibility and specificity 
of the technique, the detailed changes that can be detect-
ed by US as well as the response to therapy. Naredo et al 
[53] demonstrated that the examination of 12 anatomical 
site searching for DC and aggregates had the best results 
in terms of sensitivity and specificity. Peiteado et al [54] 
recently underlined that knees and metatarsophalangeal 
joints are the most frequently involved sites and that the 
examination of those joints bilaterally can reveal the 
presence of DCS and aggregates in 97% of cases.
Recently, Ogdieet al [55] analyzed in a systematic 
literature review and meta analysis, the usefulness of 
different imaging modalities in gout in order to develop 
new classification criteria including imaging modalities. 
Eleven studies (7 on US) examining the sensitivity and 
specificity of imaging modalities in comparison to MSU 
crystals demonstration were included in this review. 
They concluded that imaging techniques, particularly 
US, could have a promising role in the diagnosis of gout 
and classification of patients with symptomatic disease. 
However, all the included studies were accomplished on 
a small number of patients with longstanding, established 
disease. Most of the studies were case-control reports. 
Finally, there was no homogeneity in the protocols and in 
the examined sites; further studies focusing on patients 
with early onset gout are necessary and standardization 
of the methodology for US is strongly needed.
Chowalloor et al [41] published the first systematic 
review focused on the validity, reliability, responsiveness, 
and feasibility of US-detected alterations not only in gout 
but also in asymptomatic hyperuricaemia. Eighteen stud-
ies were included: 14 regarding gout, 3 asymptomatic 
hyperuricemia, and one study with both conditions. The 
US findings studied in the review were tophi, articular car-
tilage abnormalities, soft tissue abnormalities, and bony 
lesions. US showed a good constructive validity in the de-
tection of tophi when compared with MRI, as standard. 
It was also sensitive to change and demonstrated a satis-
factory inter- and intra-observer reliability. In most cases, 
tophi were described as hyperechoic, with heterogene-
ous appearance with calcifications; sometimes they were 
grouped and had a poorly defined border and posterior 
acoustic shadowing. The heterogeneity of the description 
of the tophi in the different studies may underline the need 
for standardization of definitions to improve US validity 
and reliability. The presence of tophi was documented not 
only in symptomatic and not symptomatic gout, but also in 
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subjects with hyperuricaemia. Concerning cartilage, most 
studies referred to the DCS. DCS was found in gout as 
well as in subjects with hyperuricaemia. Inter-reader reli-
ability offered excellent results in all the examined studies. 
The responsiveness was documented by the disappear-
ance of the DCS after urate-lowering therapy. Regarding 
soft tissues abnormalities, such as joint effusion, synovial 
hypertrophy, intra-articular Doppler signal, intra-articular 
hyperechogenicity, tendon lesions, and soft tissue oedema, 
these were commonly found in the explored joints in gout 
as in all the other rheumatologic pathologies. In particular, 
US seemed to be useful in detecting active inflammation in 
gout by means of power-Doppler US in comparison with 
the clinical examination. Nonetheless, the presence of 
power-Doppler signal is sensitive rather than specific for 
the diagnosis of gout. The presence of findings indicating 
intra-articular MSU crystal deposition is widely addressed 
in the literature. This occurrence is highly suggestive of 
gout, however, without concordant results. US seems also 
capable of detecting erosions and demonstrated that it was 
a valid tool compared with MRI and CR. Indeed, it re-
sulted in being even more sensitive, but less specific, than 
CR. Responsiveness of US to erosions was not reported 
when reliability was excellent. 
Several aspects arise from the systematic review of 
Chowalloor et al [14] demonstrating that US is a promis-
ing tool in the diagnosis and management of gout. None-
theless, a number of limitations are still present. 
In terms of responsiveness, recently Ottavianiet al [56] 
developed a new study to determine the ability of US to 
show decrease or disappearance of urate deposits in gouty 
patients requiring urate-lowering therapy (ULT). They 
studied 16 male patients. Serum uric acid levels and US 
examination of knees and first metatarsophalangeal joints 
were registered at baseline and after six months of ULT. 
The four patients who had not achieved the target level of 
uric acid, showed a persistence of US features. Among the 
remaining 12 patients, US abnormalities (tophi or DCS) 
disappeared or decreased in all but one who had a stable 
DCS. The correlation between the whole US examination 
and uric acid level was excellent. This study confirmed that 
US correlates with efficacy of ULT, showing disappearance 
of specific signs of disease. Thus, it can be a useful tool not 
only in the diagnosis of gout but also in the follow up.
Peiteado et al [57] recently evaluated changes of 
Doppler signal during ULT in 24 patients. Knees and the 
first metatarsophalangeal joint were evaluated by US at 
baseline and at one and two years of follow up. Doppler 
US findings showed significant improvement after ULT 
in gout patients. Interestingly, Doppler signal persistence 
after two years of treatment was still evident, suggesting 
that current treatments are probably not effective.
Clinical diagnosis of gout is sometimes difficult and 
the role of US in the assessment of gouty patients is 
increasing. Taylor et al [58], in a recent study that in-
cluded 938 patients with at least one tophus or one swol-
len joints, aimed to determine the most accurate clinical, 
laboratory, and imaging features, to differentiate patients 
with or without gout. They discriminated 10 key fea-
tures; particularly, they showed that US findings added 
discriminating value and should be included in new and 
more accurate classification criteria.
US has another important role in the diagnosis of 
gout. As described, the direct visualization of crystals in 
synovial effusion, biopsies, or tophi is the gold standard 
diagnostic tool [9]. US can identify the site to perform 
the aspiration or the biopsy and can make the procedure 
easier and safer. Slot et al [59] recently reported the re-
sults from 9 consecutive patients newly suspected of hav-
ing gout, with no effusion or tophi, who underwent dry 
needle synovial tissue aspiration in order to detect MSU 
crystals. Crystals were found in 8 of the 9 patients; no 
adverse effects were described. Usefulness of US is thus 
supported also in this field.
Moreover, intraarticular corticosteroid injection is 
considered an effective and safe therapeutic option in 
acute gouty arthritis, when nonsteroidal anti-inflammato-
ry drugs and oral therapy are not tolerated, not effective, 
or contraindicated. US guidance enables a more accurate 
and safe procedure. Ho Kang et al [60] reported their ex-
perience in 21 patients with acute gout attack involving 
the first metatarsophalangeal joint, unilaterally. US was 
more sensitive than CR in detecting erosion and tophus-
like lesion. US-guided intraarticular corticosteroid injec-
tion allowed a reduction of pain after 48 hours and there 
were no adverse events in none of the patients.
Finally, a few studies were focused on inter- and in-
tra-observer reliability and feasibility was not addressed 
at all. This may lead to the perception of US as a highly 
user-dependent technique, possibly requiring a discrete 
amount of time especially in those cases with multiple 
joints and lesions.
The standardization and validation of US abnormali-
ties is of fundamental importance in order to adopt US as 
a reference imaging method for gout diagnosis.
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